AI assistant
Sending…
RESMED INC — Director's Dealing 2020
Jan 15, 2020
30071_dirs_2020-01-14_06a3e7ab-f89d-4e4c-bf78-cf161dac9b67.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2020-01-13
Reporting Person: Farrell Michael J. (Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-13 | ResMed Common Stock | M | 6651 | $43.63 | Acquired | 361351 | Direct |
| 2020-01-13 | ResMed Common Stock | S | 6651 | $157.4281 | Disposed | 354700 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-01-13 | ResMed Common Stock Options | $43.63 | M | 6651 | Disposed | 2020-03-01 | ResMed Common Stock (6651) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| ResMed Common Stock | 8970 | Indirect |
Footnotes
F1: The transaction was conducted under a Rule 10b5-1 plan.
F2: This transaction was executed in multiple trades at prices ranging from $156.44 to $158.49. The price reported above reflects the weighted average sale price.
F3: Represents date options first became exercisable. Options vest 1/3 per year.
More from RESMED INC
Regulatory Filings
2026
May 26
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 10
Regulatory Filings
2026
Feb 9
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 3
Interim / Quarterly Report
2026
Jan 30
Regulatory Filings
2026
Jan 29